# A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

> **NCT04311710** · PHASE1 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 21 (actual)

## Conditions studied

- Tumor

## Interventions

- **DRUG:** ipilimumab
- **DRUG:** nivolumab
- **DRUG:** ENHANZE (rHuPH20)
- **DRUG:** nivolumab

## Key facts

- **NCT ID:** NCT04311710
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-25
- **Primary completion:** 2021-01-14
- **Final completion:** 2023-01-18
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2023-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04311710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04311710, "A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04311710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*